TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

Laurence Klotz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.